MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.490
-0.010
-0.22%
Opening 13:52 08/13 EDT
OPEN
4.500
PREV CLOSE
4.500
HIGH
4.500
LOW
4.410
VOLUME
40.75K
TURNOVER
--
52 WEEK HIGH
7.38
52 WEEK LOW
3.020
MARKET CAP
94.80M
P/E (TTM)
-3.8915
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GLMD stock price target is 19.86 with a high estimate of 33.00 and a low estimate of 8.00.

EPS

GLMD News

More
Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 4d ago
Galmed EPS beats by $0.06
Galmed (NASDAQ:GLMD): Q2 GAAP EPS of -$0.26 beats by $0.06. As of June 30, 2020, cash and equivalents of $5.55M vs. $15.93M as of December 31, 2019. Press
seekingalpha · 08/06 16:03
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or
PR Newswire · 08/06 11:00
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.
PR Newswire · 08/06 10:50
Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the treatment of nonalc
PR Newswire · 07/30 12:30
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential
On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the epitome of risk/reward plays. Why? It comes down to the nature of the industry itself. Healthcare companies are unique in that
TipRanks · 07/14 21:31
IPO Update: Inventiva SA Looks For $102 Million U.S. IPO
Seeking Alpha - Article · 07/06 21:58

Industry

Biotechnology & Medical Research
+0.91%
Pharmaceuticals & Medical Research
-1.14%

Hot Stocks

Symbol
Price
%Change

About GLMD

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
More

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.